Status:
UNKNOWN
Correlation of VEGF-A and Fluid Balance in Septic Shock
Lead Sponsor:
University Hospital, Rouen
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
VEGF is a key molecule in the control of vascular permeability via interactions with the VEGF-receptor on the endothelial cell. Several authors reported plasma VEGF levels are elevated in sepsis shock...
Eligibility Criteria
Inclusion
- Patient above 18 years old
- Patient with septic shock (presence of an infection, hypotension with mean arterial pressure less than 65mmHg and the need for vasopressor treatment (minimum dose 0,3µ/kg/min)
- Person informed and signed consent.
Exclusion
- Death predicted within 24 hours
- Limitation of therapeutic attitudes
- Treatment with bevacizumab in the past 6 months
- Pathologies with endothelial dysfunction (scleroderma, clarkson syndrome...)
- Acute renal failure (KDIGO 3) at ICU admission defined by :
- Increase in serum creatinine to \> 354µmol/l or 3 times baseline OR
- Urine output ≤0,3 ml/kg/h for 24h OR
- Anuria for 12h
- Morbid obesity with a body mass index (BMI) \> 35 kg/m².
- Limb amputation
- Morbid obesity with a body mass index (BMI) \> 35 kg/m².
- Amputation of a limb
- Pregnant or nursing women
- Inability to obtain consent from family
- Person with guardianship or curatorship
Key Trial Info
Start Date :
December 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 24 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04474431
Start Date
December 24 2019
End Date
January 24 2022
Last Update
November 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Rouen
Rouen, France